PMID- 21814842
OWN - NLM
STAT- MEDLINE
DCOM- 20130422
LR  - 20221207
IS  - 1880-4233 (Electronic)
IS  - 1340-6868 (Linking)
VI  - 19
IP  - 4
DP  - 2012 Oct
TI  - Study on the state of implementation of HER2 testing and positive ratios in 
      patients with breast cancer in the Kyushu-Okinawa region of Japan.
PG  - 315-20
LID - 10.1007/s12282-011-0295-0 [doi]
AB  - BACKGROUND: The development of molecular-targeted agents has improved the 
      recovery rate for cancer. In Japan, trastuzumab has been approved as an adjuvant 
      treatment for human epidermal growth factor receptor-2 (HER2)-positive breast 
      cancer; therefore, accurate management of HER2 testing has become more important. 
      In addition, proper patient selection is required from the viewpoint of health 
      care economics. METHODS: The current situation of HER2 testing in patients with 
      infiltrating breast cancer from April 2008 to March 2009 was evaluated in 49 
      institutions (50 departments) treating breast cancer in the Kyushu-Okinawa 
      region. RESULTS: In a total of 5286 samples, HER2-positive ratio was 14.2%, which 
      may reasonably reflect the current state of HER2 testing for breast cancer in the 
      Kyushu-Okinawa region. There was a moderate discrepancy in HER2-positive ratio 
      between institutions. Immunohistochemistry (IHC) analysis was outsourced in 15 
      institutions, and fluorescence in situ hybridization (FISH) analysis was 
      outsourced in 23 institutions. The ratio of retesting by FISH analysis for 
      samples judged as 2+ on IHC was 86.1%. There was no correlation between 
      HER2-positive ratio and the number of HER2 tests at the institution. However, a 
      high percentage of HER2 IHC 0-1+ results and a low percentage of HER2 2+ and 3+ 
      results at the institution were significantly correlated with a high percentage 
      of HER2 FISH-positive results for HER2 IHC 2+ cases. CONCLUSIONS: There is a 
      moderate discrepancy in HER2-positive ratio between institutions. Institutions 
      with a high percentage of HER2 IHC 0-1+ and a low percentage of HER2 2+ and 3+ 
      may have more false negative cases. These institutions should perform internal 
      accuracy evaluations in order to maintain proper diagnostic judgment.
FAU - Sagara, Yasuaki
AU  - Sagara Y
AD  - Department of Breast Surgery, Hakuaikai Sagara Hospital, 3-31 Matsubara-cho, 
      Kagoshima, Kagoshima, 892-0833, Japan. yasuaki@sagara.or.jp
FAU - Kamada, Yoshihiko
AU  - Kamada Y
FAU - Yamamoto, Yutaka
AU  - Yamamoto Y
FAU - Tanaka, Maki
AU  - Tanaka M
FAU - Kubo, Makoto
AU  - Kubo M
FAU - Yamaguchi, Rin
AU  - Yamaguchi R
FAU - Nishimura, Reiki
AU  - Nishimura R
FAU - Mitsuyama, Shoshu
AU  - Mitsuyama S
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20110804
PL  - Japan
TA  - Breast Cancer
JT  - Breast cancer (Tokyo, Japan)
JID - 100888201
RN  - 0 (Reagent Kits, Diagnostic)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Asian People
MH  - Breast Neoplasms/*metabolism
MH  - False Negative Reactions
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Japan
MH  - Reagent Kits, Diagnostic
MH  - Receptor, ErbB-2/*analysis/metabolism
MH  - Surveys and Questionnaires
EDAT- 2011/08/05 06:00
MHDA- 2013/04/23 06:00
CRDT- 2011/08/05 06:00
PHST- 2011/02/06 00:00 [received]
PHST- 2011/07/05 00:00 [accepted]
PHST- 2011/08/05 06:00 [entrez]
PHST- 2011/08/05 06:00 [pubmed]
PHST- 2013/04/23 06:00 [medline]
AID - 10.1007/s12282-011-0295-0 [doi]
PST - ppublish
SO  - Breast Cancer. 2012 Oct;19(4):315-20. doi: 10.1007/s12282-011-0295-0. Epub 2011 
      Aug 4.